Federal grant · project grant (b)
On-chip Assay for Identifying Candidate Microtubule Binding Drugs to Treat Adrds - Abstract Microtubules (MTS) Are Structurally and Functionally Essential Components of Neurons, Providing Spatial Organization and Ensuring Intracellular Trafficking. MTS Are Chemically and Functionally Heterogeneous Structures Regulated by a Complex Molecular Machinery That Can Modulate Their Composition, Chemical Modification, and Propensity for Binding With Specific Mt-associated Proteins (maps). Dysfunctions of Maps Are Directly Associated With Different Forms of Alzheimer’s Disease Related Disorders (adrds). This Notion Led to the Development of Compounds Restoring the Correct Functioning of MTS and, Therefore, Counteracting Neurodegeneration. However, Currently This Effort Requires the Use of Methods That Are Costly, Time Consuming and Inefficient, as It Requires the Use of Cell Cultures and Animal Models. We Propose to Develop an On-chip Functional Assay for Identifying Candidate Mt-binding Drugs to Treat Adrds. Our On-chip Assay Will Replicate Key Features of the Neuronal MT Microenvironment and Will Use in Vitro Generated MTS With Kinesin Based Read Out System to Measure the Ability of Potential Drugs to Stabilize and Affect MT Transport. We Will Validate the Assay Using MT Associated Protein Tau and Known MT Stabilizing Drugs. the Phase I Funding Will Allow Us to Develop a Proof-of-concept On-chip Assay That Can Be Further Developed in Phase Ii. the Proposed Chip Will Provide a Novel Ad/adrd Cell-free in Vitro Model System That Could Be Used in the Translation Process to Perform High- Throughput Screening for Drug Discovery and Drug Efficacy and Functionally Validate Therapeutic Target(s).
Committed
$514,862
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .
Loading…